Skip to main content

Longeveron, Inc. (LGVN)

NASDAQ: LGVN · IEX Real-Time Price · USD
3.53
+0.05 (1.44%)
After-hours:Sep 20, 2021 6:21 PM EDT
3.48
-0.14 (-3.87%)
At close: Sep 20, 4:00 PM
Market Cap66.52M
Revenue (ttm)3.91M
Net Income (ttm)n/a
Shares Out3.41M
EPS (ttm)-0.55
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume90,291
Open3.54
Previous Close3.62
Day's Range3.43 - 3.66
52-Week Range3.27 - 12.48
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 12, 2021

About LGVN

Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypo...

IndustryBiotechnology
IPO DateFeb 12, 2021
Employees12
Stock ExchangeNASDAQ
Ticker SymbolLGVN
Full Company Profile

Financial Performance

In 2020, Longeveron's revenue was $5.63 million, a decrease of -0.18% compared to the previous year's $5.64 million. Losses were -$3.72 million, 25.7% more than in 2019.

Financial Statements

News

LGVN Investor Alert: Rosen, Global Investor Counsel, Encourages Longeveron Inc. Investors with Losses Over $100K to S...

New York, New York--(Newsfile Corp. - September 19, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securiti...

1 day ago - Newsfile Corp

LGVN Investor News: Rosen, Top Ranked Investor Counsel, Encourages Longeveron Inc. Investors with Losses to Secure Co...

NEW YORK, Sept. 18, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Longeveron In...

2 days ago - PRNewsWire

LONGEVERON ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Longeveron...

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for ...

3 days ago - Business Wire

SHAREHOLDER ALERT: Robbins LLP Announces that Longeveron Inc. (LGVN) is Being Sued for Misleading Shareholders

SAN DIEGO--(BUSINESS WIRE)---- $LGVN #classaction--Longeveron Inc. (LGVN) Materially Misrepresented the Viability of its Lead Product Lomecel-B

3 days ago - Business Wire

LGVN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Longeveron Inc. Investors of Class Action and Enc...

NEW YORK, Sept. 17, 2021 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or ...

3 days ago - PRNewsWire

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc....

LOS ANGELES, Sept. 16, 2021 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. ("Longeveron" or ...

4 days ago - PRNewsWire

LGVN INVESTOR LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Mot...

New York, New York--(Newsfile Corp. - September 16, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no late...

4 days ago - Newsfile Corp

LGVN SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been...

NEW YORK, Sept. 15, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who p...

5 days ago - PRNewsWire

Heart Hope: Announcing the Encouraging Results of a Cell-Therapy Clinical Study by Longeveron

Photo by jesse orrico on Unsplash Researchers in the medical field are constantly working to create medicines to prevent and cure diseases. The development of the multiple COVID-19 vaccines from Pfizer ...

5 days ago - Benzinga

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron In...

LOS ANGELES--(BUSINESS WIRE)---- $LGVN #LGVN--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc.

5 days ago - Business Wire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. ...

LOS ANGELES--(BUSINESS WIRE)---- $LGVN #LGVN--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc.

6 days ago - Business Wire

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Longeveron Inc. Investors with Losses to Secure Counsel Before...

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Longeveron Inc. (NASDAQ: LG...

6 days ago - Business Wire

Pomerantz Law Firm Announces the Filing of a Class Action Against Longeveron Inc. and Certain Officers - LGVN

NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and certain of its offi...

1 week ago - PRNewsWire

Longeveron Partners with Kinesiometrics to Create and Implement Cutting-Edge Smart Phone App to Measure Physical Resp...

On the heels of Longeveron's recent announcement showing Lomecel-B significantly increased walking distance in older, frail subjects, Longeveron intends to implement Kinesiometrics new digital data-driv...

1 week ago - GlobeNewsWire

Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrom...

--Study meets primary safety endpoint: no major adverse cardiac events (MACE), nor any treatment-related infections during the first month post-treatment.  --Secondary endpoints measured per protocol su...

1 week ago - Benzinga

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Longeveron Inc. - LGVN

New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN). Such investors ar...

1 month ago - Newsfile Corp

Longeveron: Time to Buy the Dip

Longeveron Inc. ( LGVN , Financial) is an emerging clinical-stage biotechnology player that utilizes stem cell research. It is working towards developing regenerative medication via allogeneic mesenchym...

1 month ago - GuruFocus

Longeveron Inc: Time to Buy the Dip

Longeveron Inc. ( LGVN , Financial) is an emerging clinical-stage biotechnology player that utilizes stem cell research. It is working towards developing regenerative medication via allogeneic mesenchym...

1 month ago - GuruFocus

Longeveron Spikes As Lead Drug Produces Dose-Dependent Response In Aging Frailty Study; Primary Endpoint Not Met

Florida-based biopharma Longeveron Inc. (NASDAQ: LGVN), which is engaged in the development of cell therapies for chronic age-related and life-threatening conditions, announced Friday results for a mid-...

1 month ago - Benzinga

Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty

-- Study meets one of the two analyses of primary efficacy endpoint: statistically significant dose-response in six-minute walk test (6MWT) at Day 180

1 month ago - GlobeNewsWire

Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Longeveron to hold conference call today at 8:00 AM EDT Longeveron to hold conference call today at 8:00 AM EDT

1 month ago - GlobeNewsWire

Longeveron to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 13, 2021

MIAMI, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and li...

1 month ago - GlobeNewsWire

Longeveron's Novel Therapy Looks to Tackle COVID-19, Flu-Related ARDS

Photo by Anna Shvets from Pexels Now more than ever, regenerative medicine companies like Mesoblast (NASDAQ: MESO), Celularity (NASDAQ: CELU), Athersys (NASDAQ: ATHX), and Pluristem Therapeutics (NASDAQ...

1 month ago - Benzinga

Longeveron's Founders Hopeful That With Continued Clinical Trial Success, Lomecel-B May Win Regulatory Approval

Longeveron Inc. (NASDAQ: LGVN) is optimistic it could receive regulatory approvals in different countries for its lead regenerative medicine product Lomecel-B (cell-based therapy) after promising result...

2 months ago - Benzinga

Longeveron Announces Two Abstracts Accepted for Presentation at the Gerontological Society of America 2021 Annual Sci...

MIAMI, June 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and l...

2 months ago - GlobeNewsWire